Vedanta Biosciences Highlights Advances in Microbiome-Based Therapeutics at ESCMID 2026 Global Congress
Vedanta Biosciences, a late clinical-stage biopharmaceutical company focused on developing microbiome-based oral therapies for gastrointestinal diseases, has announced its participation in the upcoming European Society of Clinical Microbiology and Infectious Diseases Congress 2026, scheduled to take place from April 17–21, 2026, in Munich. The company will present new scientific data highlighting two of its leading investigational programs—VE303 and VE707—both of which are based on defined bacterial consortia designed to address serious infectious disease challenges.
The presentations underscore Vedanta’s continued progress in advancing microbiome therapeutics, a rapidly evolving field that seeks to harness the beneficial functions of commensal bacteria to prevent and treat disease. By focusing on precisely defined combinations of bacterial strains, the company aims to create targeted, reproducible therapies capable of restoring microbial balance and improving patient outcomes.
One of the key highlights of Vedanta’s presence at the congress will be a poster presentation centered on VE303, an investigational therapy being developed for the prevention of recurrent Clostridioides difficile infection (CDI). VE303 is composed of eight carefully selected bacterial strains and has already demonstrated promising results in clinical testing. In a Phase 2 study, the therapy achieved more than an 80 percent reduction in the odds of CDI recurrence compared with placebo, marking a significant advancement in a field where recurrence rates remain a major clinical concern.
The poster, titled “Impact of a Defined Bacterial Consortium on Host Immune Response and Gut Function in Patients with CDI,” will be presented by researcher Jason Norman during an ePoster flash session on April 18. The research draws on findings from the CONSORTIUM Study, a clinical investigation examining how VE303 interacts with the host environment at a molecular level. By analyzing gene expression profiles from exfoliated gut cells found in patient stool samples, researchers were able to gain insight into how the therapy influences gut health and immune responses.
The findings suggest that successful colonization of VE303 is associated with reduced markers of epithelial stress, mucosal injury, and inflammation—factors that are known to contribute to the recurrence of Clostridioides difficile infection. These results provide important mechanistic evidence supporting the clinical efficacy observed in earlier trials and reinforce the potential of microbiome-based therapies to address persistent infections in a novel way.
This research has been supported, in part, by funding from the Biomedical Advanced Research and Development Authority (BARDA), operating under the U.S. Department of Health and Human Services. Such support reflects the broader public health importance of developing new strategies to combat infectious diseases, particularly those associated with high recurrence rates and antibiotic resistance.
In addition to the VE303 poster, Vedanta Biosciences will deliver an oral presentation focused on VE707, another investigational microbiome therapeutic candidate. VE707 is designed to prevent infections caused by Gram-negative pathogens by reducing their colonization in the gastrointestinal tract. Unlike traditional antibiotics, which can disrupt the natural microbiome, VE707 aims to restore microbial balance while selectively inhibiting harmful organisms.
The oral presentation, titled “VE707, a Live Biotherapeutic Product, Reduces Intestinal Vancomycin-resistant Enterococci in a Murine Model,” will take place on April 19. The data to be presented are derived from preclinical studies using a mouse model, providing early evidence of the therapy’s potential effectiveness.
Notably, while VE707 was initially developed to target Gram-negative pathogens, the research reveals that it also significantly reduces levels of vancomycin-resistant Enterococcus (VRE), a highly problematic and drug-resistant organism. The study demonstrated a reduction in VRE levels by more than 1,000-fold compared with control groups. This finding highlights the broader therapeutic potential of VE707 and suggests that microbiome-based approaches may offer versatile solutions for combating antimicrobial-resistant infections.
The development of VE707 has been supported by CARB-X, a global partnership dedicated to accelerating the development of new antibacterial treatments. Funding for this initiative includes contributions from multiple organizations, including the U.S. Department of Health and Human Services, Wellcome, the Bill & Melinda Gates Foundation, and the Novo Nordisk Foundation, among others. This collaborative funding model underscores the urgent global need to address antimicrobial resistance through innovative scientific approaches.
Together, the presentations on VE303 and VE707 highlight Vedanta’s leadership in the field of microbiome therapeutics and its commitment to addressing some of the most pressing challenges in infectious disease management. By leveraging defined bacterial consortia, the company is pioneering a new class of treatments that move beyond traditional antibiotics and focus on restoring the natural balance of the human microbiome.
As the scientific community gathers at the European Society of Clinical Microbiology and Infectious Diseases Congress 2026, Vedanta’s contributions are expected to generate significant interest among researchers, clinicians, and public health experts. The data being presented not only advance understanding of microbiome-based therapies but also point toward a future in which such treatments play a central role in preventing and managing infectious diseases.
With ongoing clinical and preclinical development efforts, Vedanta Biosciences continues to build a robust pipeline aimed at transforming how infections are treated. Its work represents a promising step forward in the global effort to reduce the burden of recurrent infections and combat the growing threat of antimicrobial resistance.
About Vedanta Biosciences
Vedanta Biosciences is a late clinical-stage biopharmaceutical company developing a new category of microbiome-based oral therapies for gastrointestinal diseases. Vedanta’s lead program, VE303, is currently being evaluated in the global Phase 3 RESTORATiVE303 registrational study for the prevention of recurrent C. difficile infection.
Source Link:https://www.businesswire.com/
